Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Serum prostate-specific antigen determination in prostatic carcinoma.

A Tizzani1, G Casetta, P Piana

  • 1Institute of Nephro-Urology, University of Torino, Italy.

The International Journal of Biological Markers
|September 1, 1987
PubMed
Summary

Prostate-specific antigen (PSA) levels alone, using a 10 ng/ml cut-off, are insufficient for early prostate cancer detection. Combining PSA with prostatic acid phosphatase (PAP) may improve early diagnosis of prostate cancer.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[The gut-brain axis in attention deficit hyperactivity disorder: the role of the microbiota].

Revista de neurologia·2018
Same author

[Treatment of attention deficit hyperactivity disorder in adults using virtual reality through a mindfulness programme].

Revista de neurologia·2017
Same author

The clinical use of statistical permutation test methodology: a tool for identifying predictive variables of outcome.

Urologia internationalis·2014
Same author

Effect of the serotonin transporter gene and of environment on the continuity of anxiety and depression traits throughout adolescence.

Epidemiology and psychiatric sciences·2013
Same author

Meningococcal X polysaccharide quantification by high-performance anion-exchange chromatography using synthetic N-acetylglucosamine-4-phosphate as standard.

Analytical biochemistry·2013
Same author

Psychopathology and adversities from early- to late-adolescence: a general population follow-up study with the CBCL DSM-Oriented Scales.

Epidemiology and psychiatric sciences·2012

Area of Science:

  • Urology
  • Biochemistry
  • Oncology

Background:

  • Prostate-specific antigen (PSA) is a key biomarker synthesized in the prostate.
  • Prostatic acid phosphatase (PAP) is another marker associated with prostate function.
  • Early detection of prostate cancer remains a significant clinical challenge.

Purpose of the Study:

  • To evaluate the efficacy of Prostate-specific antigen (PSA) as an early predictor of prostatic carcinoma.
  • To investigate the combined utility of PSA and prostatic acid phosphatase (PAP) in diagnosing prostate cancer.

Main Methods:

  • A study involving 199 subjects categorized into four groups: young controls, older controls, benign prostatic hyperplasia (BPH) patients, and prostate cancer patients.
  • Established a PSA cut-off value of 10 ng/ml, based on the mean BPH group value plus 2 standard deviations.

Related Experiment Videos

  • Assessed PSA and PAP levels in relation to disease status.

    • Main Results:

    • The defined PSA cut-off value of 10 ng/ml demonstrated limited ability to predict early-stage prostatic carcinoma.
    • Elevated PSA levels were observed in patients with BPH and prostate cancer.
    • The concurrent measurement of PSA and PAP showed potential for increasing the detection rate of positive biological markers in prostate cancer patients.

    Conclusions:

    • A PSA cut-off of 10 ng/ml is not sufficiently sensitive for the early diagnosis of prostate cancer.
    • The combined assessment of PSA and PAP may enhance the identification of prostate cancer, particularly in cases with positive biological markers.